Histatin-derived peptides: Potential agents to treat localised infections

Expert Opinion on Emerging Drugs

Volumn 7, Issue 1, 2002, Pages 47-59

  Rothstein, David M ^a   Helmerhorst, Eva J ^a   Spacciapoli, Peter ^a   Oppenheim, Frank G ^a   Friden, Phillip ^a  

^a NONE   (United States)

Author keywords

Antibacterial; Antibiotics; Antifungal; Antimicrobial peptide; Cystic fibrosis; Gingivitis; Histatin; Mucositis; Oral candidiasis; Periodontal disease

Indexed keywords

ANTIINFECTIVE AGENT; HISTATIN; HISTATIN 1; HISTATIN 3; HISTATIN 5; PEPTIDE; PLACEBO; SARALASIN; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; CANDIDA ALBICANS; CLINICAL TRIAL; CYSTIC FIBROSIS; DOG; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GEL; GINGIVITIS; HUMAN; INFECTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUTHWASH; MUCOSA INFLAMMATION; PERIODONTAL DISEASE; PROTEIN MODIFICATION; REVIEW; SIDE EFFECT; SKIN INFECTION; STRUCTURE ACTIVITY RELATION; THRUSH;

EID: 0036078811     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.7.1.47     Document Type: Review

References (91)

1. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance
2. Antifungal peptides: Novel therapeutic compounds against emerging pathogens
3. Cationic peptides: A new source of antibiotics
4. Peptide antibiotics
5. Cationic antimicrobial peptides: Towards clinical applications
6. The primary structure and functional characterization of the neutral histidine-rich polypeptide from human parotid secretion
7. Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans
8. Human salivary histatins: Promising anti-fungal therapeutic agents
9. Salivary histatins in patients with recurrent oral candidiasis
10. Adsorption of human salivary proteins to hydroxyapatite: A comparison between whole saliva and glandular salivary secretions
11. Inhibitory effects of synthetic histidine-rich peptides on haemagglutination by Bacteroides gingivalis 381
12. Inhibitory effects of human salivary histatins and lysozyme on coaggregation between Porphyromonas gingivalis and Streptococcus mitis
13. Salivary histatin as an inhibitor of a protease produced by the oral bacterium Bacteroides gingivalis
14. Histatin 5 is a potent competitive inhibitor of the cysteine proteinase clostripain
15. Salivary histatin 5 is an inhibitor of both host and bacterial enzymes implicated in periodontal disease
16. Anti-lipopolysaccharide activity of histatins, peptides from human saliva
17. Inhibitory effect of synthetic histatin 5 on leukotoxin from Actinobacillus actinomycetemcomitans
18. The crisis in antibiotic resistance
19. The challenge of antibiotic resistance
20. Antifungals: Mechanism of action and resistance, established and novel drugs
21. Fungistatic and fungicidal activity of human parotid salivary histidine-rich polypeptides on Candida albicans
22. Salivary histatin 5: Dependence of sequence, chain length, and helical conformation for candidacidal activity
23. Anticandidal activity of major human salivary histatins
24. Salivary antimicrobials: Where are we?
25. Salivary proteolysis of histidine-rich polypeptides and the antifungal activity of peptide degradation products
26. Amphotericin B- and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides
27. Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5
28. Human salivary histatin-5 exerts potent fungicidal activity against Cryptococcus neoformans
29. Growth-inhibitory and bactericidal effects of human parotid salivary histidine-rich polypeptides on Streptococcus mutans
30. P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients
31. Identification and characterization of the antimicrobial peptide corresponding to C-terminal beta-sheet domain of tenecin 1, an antibacterial protein of larvae of Tenebrio molitor
32. Antimicrobial properties of peptides from Xenopus granular gland secretions
33. Membrane-induced helical conformation of an active candidacidal fragment of salivary histatins
34. Characterization of histatin 5 with respect to amphipathicity, hydrophobicity, and effects on cell and mitochondrial membrane integrity excludes a candidacidal mechanism of pore formation
35. Synthetic histatin analogues with broad-spectrum antimicrobial activity
36. Membrane proteins: From sequence to structure
37. Peptide antibiotics
38. Candidacidal activity of human salivary histatin recombinant variants produced by site-directed mutagenesis
39. Candidacidal activity of recombinant human salivary histatin-5 and variants
40. Role of alpha-helical conformation of histatin-5 in candidacidal activity examined by proline variants
41. Recombinant histatins: Functional domain duplication enhances candidacidal activity
42. Construction and characterization of human salivary histatin-5 multimers
43. The effects of hisratin-derived basic antimicrobial peptides on oral biofilms
44. Stabilization of helix by side-chain interactions in histatin-derived peptides: Role in candidacidal activity
45. A critical comparison of the hemolytic and fungicidal activities of cationic antimicrobial peptides
46. Evaluation of susceptibility of gram-positive and -negative bacteria to human defensins by using radial diffusion assay
47. The cellular target of histatin 5 on Candida albicans is the energized mitochondrion
48. Histatin 3-mediated killing of Candida albicans: Effect of extracellular saltconcentration on binding and internalization
49. Killing of Candida albicans by histatin 5: Cellular uptake and energy requirement
50. Candidacidal activity of salivary histatins. Identification of a histatin 5-binding protein on Candida albicans
51. Salivary histatin 5 induces non-lytic release of ATP from Candida albicans leading to cell death
52. Candida albicans mutants deficient in respiration are resistant to the small cationic salivary antimicrobial peptide histatin 5
53. The human salivary peptide histatin 5 exerts its antifungal activity through the formation of reactive oxygen species
54. Microbiology of periodontal disease - Present status and future considerations
55. Periodontal disease
56. What is gingivitis? Current understanding of prevention, treatment, measurement, pathogenesis and relation to periodontitis
57. Pharmacologic management of periodontal diseases using systemically administered agents
58. The role of local drug delivery in the management of periodontal diseases: A comprehensive review
59. Chemotherapeutic agents for controlling plaque and gingivitis
60. The role of supragingival plaque in the prevention and treatment of periodontal diseases. A review of current concepts
61. Inhibition of experimental gingivitis in beagle dogs with topical salivary histatins
62. In vivo antifungal efficacy of salivary histidine-rich polypeptides: Preliminary findings in a denture stomatitis model system
63. Checkerboard DNA-DNA hybridization
64. Safety and clinical effects of topical histatin gels in humans with experimental gingivitis
65. Periodontal disease in pregnancy (I). Prevalence and severity
66. Clinical and microbial evaluation of a histatin containing mouthrinse in humans with experimental gingivitis
67. Clinical and microbial evaluation of a histatin-containing mouthrinse in humans with experimental gingivitis: A phase 2 multi-center study
68. Efficacy of Listerine antiseptic in inhibiting the development of plaque and gingivitis
69. The effects of intra-arterial epinephrine and nicotine on gingival circulation
70. Pilot study comparing the salivary cationic protein concentrations in healthy adults and AIDS patients: Correlation with antifungal activity
71. Longitudinal study of parotid saliva in HIV-1 infection
72. Determination of salivary anticandidal activities in healthy adults and patients with AIDS: A pilot study
73. Elevation of salivary antimicrobial proteins following HIV-1 infection
74. Do microorganisms play a role in irradiation mucositis?
75. Cystic fibrosis
76. Management of pulmonary disease in patients with cystic fibrosis
77. Antimicrobial treatment of pulmonary colonization and infection by Pseudomonas aeruginosa in cystic fibrosis patients
78. Genetic and immunological aspects of cystic fibrosis
79. Dynamic interactions of biofilms of mucoid Pseudomonas aeruginosa with tobramycin and piperacillin
80. Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis
81. Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis
82. Pathogenesis of bacterial bronchitis in cystic fibrosis
83. Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections
84. Microbial pathogenesis in cystic fibrosis mucoid Pseudomonas aeruginosa and Burkholderia cepacia
85. Microbiology of sputum from patients at cystic fibrosis cneters in the United States
86. Efficacy of aerosolized tobramycin in patients with cystic fibrosis
87. Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed beta-lactamase producing strains
88. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum
89. Macromoleculas mechanisms of sputum inhibition of tobramycin activity
90. The binding of anti- pseudomonal antibiotics to macomolecules from cystic fibrosis sputum
91. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: Comparison with activity in serum